Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Recurrence 5Lymphoma 5Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Hematologic Neoplasms 2Burkitt Lymphoma 2Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Prolymphocytic 1Leukemia 1Hodgkin Disease 1

Interventions

Temozolomide 2Lenalidomide 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclophosphamide 2venetoclax 1trametinib 1toripalimab 1tafasitamab 1sonidegib 1ribociclib 1fludarabine 1etoposide phosphate 1camrelizumab 1brivanib 1apatinib 1acalabrutinib 1Vincristine 1Valganciclovir 1Thiotepa 1Therapeutics 1Telemedicine 1Tamoxifen 1Surveys and Questionnaires 1Standard of Care 1Rituximab 1Radiotherapy 1R-CHOP protocol 1Patient Navigation 1N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pyloric Stenosis, Hypertrophic × tafasitamab × Clear all
NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Xencor, Inc.

Phase 2 Terminated
3 enrolled 6 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡